article · Annals of Medicine and Surgery
Trastuzumab combinations are emerging as a promising therapeutic strategy for HER2-positive colorectal cancer. This review investigates the current clinical data on efficacy and safety. Clinical trials have shown encouraging results, with objective response rates (ORRs) ranging from 22.2 to 46% and complete remission achievable in some patients. Additionally, these combinations demonstrate potential for improved overall survival (OS). However, optimizing therapeutic strategies remains crucial. Future research should tailor treatment regimens based on tumor biology and individual patient characteristics. Investigating ctDNA genotyping as a reliable method for identifying responders and exploring the role of Rat Sarcoma Virus (RAS) mutations and other molecular markers are key areas for optimizing patient selection and treatment efficacy. Understanding resistance mechanisms is vital for developing combination therapies that overcome these pathways.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1097/ms9.0000000000004459
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
